{"id":888120,"date":"2025-09-20T11:03:24","date_gmt":"2025-09-20T15:03:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-presents-cemsidomide-phase-1-multiple-myeloma-data-supporting-potential-best-in-class-profile-at-the-international-myeloma-society-annual-meeting\/"},"modified":"2025-09-20T11:03:24","modified_gmt":"2025-09-20T15:03:24","slug":"c4-therapeutics-presents-cemsidomide-phase-1-multiple-myeloma-data-supporting-potential-best-in-class-profile-at-the-international-myeloma-society-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/c4-therapeutics-presents-cemsidomide-phase-1-multiple-myeloma-data-supporting-potential-best-in-class-profile-at-the-international-myeloma-society-annual-meeting\/","title":{"rendered":"C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting"},"content":{"rendered":"
\n

\n Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 \u00b5g) and a 40% ORR at the 75 \u00b5g Dose Level in a Heavily Pre-Treated Relapsed\/Refractory Multiple Myeloma Patient Population<\/em>\n <\/p>\n

\n Responses Across Dose Levels With Median Duration of Response of 9.3 Months as of the Data Cut-off Date; Median Duration of Response Not Yet Reached at Two Highest Doses<\/em>\n <\/p>\n

\n No Discontinuations Related to Cemsidomide and Few Dose Reductions Support a Safety Profile That May Be Ideal for Combination Regimens<\/em>\n <\/p>\n

\n C4T to Pursue Differentiated Development Strategy With Two Distinct Opportunities for Accelerated Approval in Second Line and Later<\/em>\n <\/p>\n

\n C4T to Host Webcast\u00a0Today at 3 pm ET; Webcast Link Available <\/em>
\n
\n Here<\/em>
\n <\/a>\n <\/p>\n

WATERTOWN, Mass., Sept. 20, 2025 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today presented data from the Phase 1 clinical trial of cemsidomide, an orally bioavailable IKZF1\/3 degrader, in combination with dexamethasone for the treatment of relapsed\/refractory multiple myeloma (RRMM). With enrollment in the Phase 1 trial complete, data continue to show cemsidomide\u2019s differentiated safety and tolerability profile and potentially class-leading anti-myeloma activity, supporting clear development paths for second line and later patient populations.<\/p>\n

\u201cCemsidomide\u2019s clinical trial results to date have shown compelling anti-myeloma activity, a differentiated safety and tolerability profile and immunomodulatory effects across all dose levels, which have allowed us to create a derisked development plan that we are prepared to rapidly execute to potentially bring cemsidomide to patients, caregivers and hematologist-oncologists,\u201d said Len Reyno, M.D., chief medical officer of C4 Therapeutics. \u201cAs we prepare to initiate the Phase 2 study in Q1 2026 to evaluate cemsidomide in combination with dexamethasone and the Phase 1b study in Q2 2026 to evaluate cemsidomide and dexamethasone in combination with a BCMA BiTE\u2014both development pathways that have the potential for accelerated approval\u2014we are excited to further differentiate cemsidomide as the IKZF1\/3 degrader of choice among approved medicines in this class, which are used across lines of therapy and in various combination regimens. We look forward to generating data in the future that further demonstrates cemsidomide\u2019s potential to become a class-leading IKZF1\/3 degrader across the growing populations of relapsed\/refractory multiple myeloma patients.\u201d<\/p>\n

Approved IKZF1\/3 degraders remain backbone therapy across lines of multiple myeloma treatment, even as novel therapeutic approaches enter the treatment landscape. Recent advances in treatment, including immune-directed therapies, are not cures and the majority of patients ultimately relapse, creating a need for new medicines targeted at these heavily pretreated patients. This need for therapeutic options in later lines of therapy, which continue to incorporate IKZF1\/3 degradation into the treatment regimen to promote myeloma cell death and T-cell activation, is expected to grow as patients live longer on newer treatments but still ultimately progress.<\/p>\n

\u201cThe clinical data presented today for this potent Cereblon-based IKZF1\/3 degrader shows a potentially class-leading safety profile and impressive evidence of anti-myeloma activity in a population of patients with extensive prior therapies\u2014including 75% of patients who have progressed despite having received prior immune-based therapies, including BiTEs or CAR-Ts,\u201d said Binod Dhakal, M.D., M.S., associate professor of medicine, Medical College of Wisconsin, Division of Hematology. \u201cCemsidomide in combination with dexamethasone is well positioned both as a potential therapeutic option for patients with multi-refractory disease, and as the potential combination regimen of choice with immune-directed therapies due to its ability to enhance the immune response and add additional direct anti-myeloma effects via IKZF1\/3 degradation.\u201d<\/p>\n

\n
\n Phase 1 Results<\/u>
\n <\/strong>
\n
At the IMS Annual Meeting, C4T presented data from the Phase 1 dose escalation trial, for which enrollment is now complete. These data demonstrate cemsidomide\u2019s potential to have a class-leading profile based on both its anti-myeloma activity and safety and tolerability profile, which positions the investigational medicine to become the IKZF1\/3 degrader of choice across lines of therapy.<\/p>\n

As of the July 23, 2025 data cutoff, a total of 72 patients received cemsidomide in combination with dexamethasone across five dose levels (50 \u00b5g dosed Monday, Wednesday, Friday [MWF]; 37.5 \u00b5g dosed once daily [QD]; 62.5 \u00b5g QD; 75 \u00b5g QD; 100 \u00b5g QD). The trial enrolled a heavily pretreated relapsed\/refractory patient population that had received a median of seven prior therapies. Fifty-four patients (75%) received prior BCMA-targeted therapy, and 54 patients (75%) received prior CAR-T or T-cell engager therapy.<\/p>\n

\n
\n Safety<\/u>
\n <\/em>
\n : Cemsidomide in combination with dexamethasone was generally well tolerated over the range of doses tested.<\/em>\n <\/p>\n